Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents
Abstract The innovative discovery of aptamers was based on target-specific treatment in clinical diagnostics and therapeutics. Aptamers are synthetic, single-stranded oligonucleotides, simply described as chemical antibodies, which can bind to diverse targets with high specificity and affinity. Aptamers are synthesized by the SELEX technique, and possess distinctive properties as small size (10–50 kDa), higher stability, easy manufacture and less immunogenicity. These oligonucleotides are easily degraded by nucleases, so require some important modifications like capping and incorporation of modified nucleotides. RNA aptamers can be modified chemically on 2′ positions using -$ NH_{3} $, -F, -deoxy, or -OMe groups to enhance their nuclease resistance. Aptamers have been employed for multiple purposes, as direct drugs or aptamer–drug conjugates targeted against different diseased cells. Different aptamer-conjugated nanovehicles (e.g., micelles, liposomes, silica nano-shells) have been designed to transport diverse anticancer-drugs like doxorubicin and cisplatin in bulk to minimize systemic cytotoxicity. Some drug-loaded nanovehicles (up to 97% loading capacity) and conjugated with specific aptamer resulted in more than 60% tumor inhibition as compared to unconjugated drug-loaded nanovehicles which showed only 31% cancer inhibition. In addition, aptamers have been widely used in basic research, food safety, environmental monitoring, clinical diagnostics and therapeutics. Different FDA-approved RNA and DNA aptamers are now available in the market, used for the treatment of diverse diseases, especially cancer. These aptamers include Macugen, Pegaptanib, etc. Despite a good progress in aptamer use, the present-day chemotherapeutics and drug targeting systems still face great challenges. Here in this review article, we are discussing nucleic acid aptamers, preparation, role in the transportation of different nanoparticle vehicles and their applications as therapeutic agents..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
3 Biotech - 10(2020), 12 vom: 24. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Allemailem, Khaled S. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Aptamosomes |
| doi: |
10.1007/s13205-020-02546-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR042134420 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR042134420 | ||
| 003 | DE-627 | ||
| 005 | 20230519161229.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201126s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13205-020-02546-1 |2 doi | |
| 035 | |a (DE-627)SPR042134420 | ||
| 035 | |a (DE-599)SPRs13205-020-02546-1-e | ||
| 035 | |a (SPR)s13205-020-02546-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 333.7 |a 610 |q ASE |
| 084 | |a 58.30 |2 bkl | ||
| 100 | 1 | |a Allemailem, Khaled S. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent advances in understanding oligonucleotide aptamers and their applications as therapeutic agents |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The innovative discovery of aptamers was based on target-specific treatment in clinical diagnostics and therapeutics. Aptamers are synthetic, single-stranded oligonucleotides, simply described as chemical antibodies, which can bind to diverse targets with high specificity and affinity. Aptamers are synthesized by the SELEX technique, and possess distinctive properties as small size (10–50 kDa), higher stability, easy manufacture and less immunogenicity. These oligonucleotides are easily degraded by nucleases, so require some important modifications like capping and incorporation of modified nucleotides. RNA aptamers can be modified chemically on 2′ positions using -$ NH_{3} $, -F, -deoxy, or -OMe groups to enhance their nuclease resistance. Aptamers have been employed for multiple purposes, as direct drugs or aptamer–drug conjugates targeted against different diseased cells. Different aptamer-conjugated nanovehicles (e.g., micelles, liposomes, silica nano-shells) have been designed to transport diverse anticancer-drugs like doxorubicin and cisplatin in bulk to minimize systemic cytotoxicity. Some drug-loaded nanovehicles (up to 97% loading capacity) and conjugated with specific aptamer resulted in more than 60% tumor inhibition as compared to unconjugated drug-loaded nanovehicles which showed only 31% cancer inhibition. In addition, aptamers have been widely used in basic research, food safety, environmental monitoring, clinical diagnostics and therapeutics. Different FDA-approved RNA and DNA aptamers are now available in the market, used for the treatment of diverse diseases, especially cancer. These aptamers include Macugen, Pegaptanib, etc. Despite a good progress in aptamer use, the present-day chemotherapeutics and drug targeting systems still face great challenges. Here in this review article, we are discussing nucleic acid aptamers, preparation, role in the transportation of different nanoparticle vehicles and their applications as therapeutic agents. | ||
| 650 | 4 | |a Nucleic acid aptamers |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SELEX |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Aptamosomes |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Micelles |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Drug delivery |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Therapeutics |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Almatroudi, Ahmad |e verfasserin |4 aut | |
| 700 | 1 | |a Alsahli, Mohammed A. |e verfasserin |4 aut | |
| 700 | 1 | |a Basfar, Ghaiyda Talal |e verfasserin |4 aut | |
| 700 | 1 | |a Alrumaihi, Faris |e verfasserin |4 aut | |
| 700 | 1 | |a Rahmani, Arshad Husain |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Amjad Ali |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t 3 Biotech |d Berlin : Springer, 2011 |g 10(2020), 12 vom: 24. Nov. |w (DE-627)SPR030851394 |w (DE-600)2600522-0 |x 2190-5738 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:12 |g day:24 |g month:11 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13205-020-02546-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 58.30 |q ASE |
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |e 12 |b 24 |c 11 | ||